Drug Safety and PV Services

When patient safety is of the utmost importance, Sponsors trust MMS as their go-to CRO.

We are very impressed with the quality of the MMS deliverables. Excellent improvement proposals!
Oncology Clinical Lead
Top 5 Pharma

MMS provides comprehensive solutions to meet the pharmacovigilance and drug safety needs of the pharmaceutical industry today. An efficient, adaptable model enables increased productivity, enhances safety monitoring external reporting, and offers Sponsors more time to focus on strategy rather than day-to-day processing activities.

Comprehensive safety services across all phases of clinical research include:

  • Implementation and Management of safety databases, including data migration services
  • Medical safety monitoring
  • 24/7 case management
  • Serious Adverse Event (SAE) management and expedited reporting
  • Ad hoc safety analyses and risk management
  • Signal detection
  • Annual reports, periodic safety update reports (PSURs), and expert reports
  • Labeling/CCDS support
  • Literature reviews

Medical Monitoring Services
Medical monitoring experts at MMS provide medical reviews and oversight of clinical trial activities across all phases of clinical research, including first-in-human trials. Experienced medical staff bring a practical and real-world clinical perspective to assist study and sponsor teams with every aspect of subject safety. This includes ongoing collaboration with clinical trial investigators, assisting with safety event reporting and the analysis, interpretation of efficacy, safety, and outcomes data.

The MMS medical monitoring team adds value throughout the clinical trial process, including the evaluation and determination of the clinical implications of the study results.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization